Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma (GOTEL-FL1LC)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas.
Recruitment status was  Recruiting
Information provided by:
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas Identifier:
First received: July 25, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted
To evaluate the complete clinical response rate according to the International Working Group criteria with a consolidation treatment with 90Y-ibritumomab tiuxetan (Zevalin®) in patients with high-risk follicular lymphoma with either partial or complete response to R-CHOP induction chemotherapy

Condition Intervention Phase
Follicular Lymphoma
Drug: Y90 Ibritumomab Tiuxetan
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R-Chop Induction Chemotherapy

Resource links provided by NLM:

Further study details as provided by Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas:

Primary Outcome Measures:
  • CT scan of cervical spine, chest, abdomen and pelvis, Peripheral blood and bone marrow PCR to determine Minimal Residual Disease [ Time Frame: 12 weeks after consolidation, then repeated every 3 months over the first 2 years, and every 6 months thereafter ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Objective clinical response rate (complete + partial). [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Response conversion rate [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Incidence of complete molecular responses [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Response duration [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Event-free survival. [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Progression-free survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Time to salvage therapy [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Lymphoma-free or specific cause-free survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 60 months ] [ Designated as safety issue: No ]
  • Toxicity profile and safety of the consolidation [ Time Frame: 60 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 38
Study Start Date: April 2008
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1. Consolidation with Y90 Ibritumomab Tiuxetan
1. Consolidation with Y90 Ibritumomab Tiuxetan
Drug: Y90 Ibritumomab Tiuxetan
Consolidation with Y90 Ibritumomab Tiuxetan


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signature of the written informed consent by the subject or his/her legal representative before initiation of any trial specific procedure.
  • Patients older than 18.
  • Histologic diagnosis of CD20+, grade 1-3a follicular lymphoma as per the WHO classification.
  • High-risk patients according to FLIPI before initiation of induction chemotherapy.
  • Stage II-IV prior to initiation of induction treatment, or any stage in patients with grade 3 follicular lymphoma.
  • Complete or partial response to the induction scheme.
  • ECOG scale performance status 0 - 2.
  • Life expectancy greater than 3 months.
  • In women of childbearing age, use of a reliable contraceptive method.
  • A suitable bone marrow reserve:

    • Lower than 25% Bone marrow infiltration by lymphoma.
    • Hb 10 g/dL. PMN leukocytes 1,500 cel/mm3, platelets 100,000/mm3
    • Suitable hepatic, renal and cardiac function:

      • creatinine <2,5 x UNL (upper normality limit).
      • bilirubin or ALT/AST < 2,5 x UNL

Exclusion Criteria:

  • Patients with no objective clinical response to induction chemotherapy.
  • > 25% bone marrow infiltration following induction chemotherapy.
  • Platelets < 100,000 before radioimmunotherapy.
  • Severe and/or uncontrolled concomitant disease:
  • Hepatic, renal, cardiovascular, neurological or metabolic disease.
  • Cardiac failure, ischemic cardiopathy, ischemic cardiopathy with a history of myocardial infarction or angor, or major ventricular arrhythmia.
  • Positive regarding HBV, HCV, HIV.
  • Active acute or chronic infection.
  • Social, psychic or geographic disability to satisfy any of the treatment schemes.
  • Pregnant and/or breastfeeding women, or adult patients of childbearing age who are not using a safe birth control device throughout the study treatment and at least 12 months thereafter.
  • Known or suspected hypersensitivity, or confirmed or suspected adverse reaction to the study drugs and other related compounds (Rituximab, Ibritumomab tiuxetan, a history of sensitivity to murine proteins, dexametasone, cyclophosphamide and other anthracyclines, cytarabine).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00722930

Contact: Mariano Provencio, MD +34-91-344-57-60
Contact: Sandra Cerdeira, Secretary 34 91 3445131

Hospital Virgen de la Victoria Active, not recruiting
Málaga, Malaga, Spain
Instituto Oncológico San Sebastián Active, not recruiting
Donostia, San Sebastián, Spain
Hospital Universitario de Canarias Active, not recruiting
La Laguna, Santa Cruz de Tenerife, Spain
Hospital Sant Joan de Reus Active, not recruiting
Reus, Tarragona, Spain
Hospital Virgen de las Nieves Active, not recruiting
Granada, Spain
Clinia Puerta de Hierro Recruiting
Madrid, Spain
Principal Investigator: Mariano Provencio, MD         
Clínica Ruber Internacional Active, not recruiting
Madrid, Spain
Complejo Hospitalario de Pontevedra Active, not recruiting
Pontevedra, Spain
Hospital Universitario Virgen Macarena Active, not recruiting
Sevilla, Spain
Hospital Virgen de la Salud de Toledo Active, not recruiting
Toledo, Spain
Hospital Universitario La Fe Active, not recruiting
Valencia, Spain
Sponsors and Collaborators
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
Principal Investigator: Mariano Provencio, MD Clínica Puerta de Hierro
  More Information

No publications provided

Responsible Party: Dr. Mariano Provencio, Clínica Puerta de Hierro, Servicio de Oncología Médica Identifier: NCT00722930     History of Changes
Other Study ID Numbers: GOTEL-FL1LC-0701, Eudra-CT 2007-003091-19
Study First Received: July 25, 2008
Last Updated: July 25, 2008
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas:
Follicular Lymphoma
High-risk FLIPI

Additional relevant MeSH terms:
Lymphoma, Follicular
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Antibodies, Monoclonal
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on December 01, 2015